1887

Abstract

Surveillance of antibiotic susceptibility from patients in London, the largest metropolitan area in the UK, is limited, despite resistance being a key factor in treatment failure. A two-centre survey was performed over 12 months (1999–2000) to determine antibiotic-resistance rates of isolates from dyspeptic patients attending endoscopy clinics serving two ethnically diverse central and south London communities. The antibiotic susceptibilities were determined from disc diffusion and epsilometer (E) tests on 101 isolates. Overall resistance rates were 59 % for metronidazole and 11 % for clarithromycin, with 8 % resistance to both antibiotics. Corresponding primary resistance rates were 50 % and 7 %, respectively. High-level-resistance was a feature of 82 % of the metronidazole (MIC ⩾ 256 mg l) -resistant and 55 % of the clarithromycin (MIC ⩾ 32 mg l) -resistant strains. All isolates were susceptible to amoxycillin and tetracycline. No associations between resistance and either the gender or the age of the patients were detected. The main risk for resistance to metronidazole was non-UK birth as comparative rates were 68 % for non-UK vs. 40 % for UK-born individuals. Resistant isolates were genotypically diverse with respect to / type. Four 23S rDNA nucleotide polymorphisms were associated with clarithromycin resistance, mostly (9/11) at A2143G. In conclusion, the high overall metronidazole-resistance rate of 59 % for from inner London was twice the rate found in other UK-based studies and was attributed to the higher risk of resistant strains infecting individuals born outside the UK. The need for continued resistance surveillance is indicated to monitor the effects of the ‘test and treat’ strategy for eradication, particularly of isolates from at-risk individuals

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45896-0
2005-06-01
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/6/JM540610.html?itemId=/content/journal/jmm/10.1099/jmm.0.45896-0&mimeType=html&fmt=ahah

References

  1. Aceti, A., Are, R., Sabino, G., Fenu, L., Pasquazzi, C., Quaranta, G., Zechini, B. & Terrosu, P. ( 2004;). Helicobacter pylori active infection in patients with acute coronary heart disease. J Infect 49, 8–12.[CrossRef]
    [Google Scholar]
  2. Andrews, J. ( 2003;). BSAC Disc Diffusion Method for Antimicrobial Susceptibility Testing, Version 2.1.4. Birmingham, UK: British Society for Antimicrobial Chemotherapy.
  3. Banatvala, N., Davies, G. R., Abdi, Y., Clements, L., Rampton, D. S., Hardie, J. M. & Feldman, R. A. ( 1994;). High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 35, 1562–1566.[CrossRef]
    [Google Scholar]
  4. Cameron, E. A. B., Powell, K. U., Baldwin, L., Jones, P., Bell, G. D. & Williams, S. G. J. ( 2004;). Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991–2001. J Med Microbiol 53, 535–538.[CrossRef]
    [Google Scholar]
  5. Chisholm, S. A. & Owen, R. J. ( 2003;). Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother 51, 995–999.[CrossRef]
    [Google Scholar]
  6. Chisholm, S. A., Teare, E. L., Patel, B. & Owen, R. J. ( 2002;). Determination of Helicobacter pylori vacA allelic types by single-step multiplex PCR. Lett Appl Microbiol 35, 42–46.[CrossRef]
    [Google Scholar]
  7. Dore, M. P., Leandro, G., Realdi, G., Sepulveda, A. R. & Graham, D. Y. ( 2000;). Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45, 68–76.[CrossRef]
    [Google Scholar]
  8. Duck, W. M., Sobel, J., Pruckler, J. M. & 21 other authors ( 2004;). Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 10, 1088–1094.[CrossRef]
    [Google Scholar]
  9. Elviss, N. C., Owen, R. J., Xerry, J., Walker, M. & Davies, K. ( 2004a;). Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother 54, 435–440.[CrossRef]
    [Google Scholar]
  10. Elviss, N. C., Lawson, A. J. & Owen, R. J. ( 2004b;). Application of 3′-mismatched reverse primer PCR compared with real-time PCR and PCR-RFLP for the rapid detection of 23S rDNA mutations associated with clarithromycin resistance in Helicobacter pylori. Int J Antimicrob Agents 23, 349–355.[CrossRef]
    [Google Scholar]
  11. Glupczynski, Y., Mégraud, F., López-Brea, M. & Andersen, L. P. ( 2001;). European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 20, 820–823.[CrossRef]
    [Google Scholar]
  12. Glupczynski, Y., Broutet, N., Cantagrel, A., Andersen, L. P., Alarcón, T., López-Brea, M. & Mégraud, F. ( 2002;). Comparison of the E Test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 21, 549–552.[CrossRef]
    [Google Scholar]
  13. Harris, A. & Misiewicz, J. J. ( 2001;). ABC of the upper gastrointestinal tract.Management of Helicobacter pylori infection. BMJ 323, 1047–1050.
    [Google Scholar]
  14. Heep, M., Kist, M., Strobel, S., Beck, D. & Lehn, N. ( 2000;). Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19, 538–541.[CrossRef]
    [Google Scholar]
  15. Kist, M. & Glocker, E. ( 2004;). ResiNet – a nationwide German sentinel study for surveillance and analysis of antimicrobial resistance in Helicobacter pylori. Eurosurveillance 9, 44–45.
    [Google Scholar]
  16. Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A. P., Jones, R., Axon, A., Graham, D. Y., Tytgat, G. & European Helicobacter pylori Study Group ( 2002;). Current concepts in the management of Helicobacter pylori infection – the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16, 167–180.
    [Google Scholar]
  17. Meyer, J. M., Silliman, N. P., Wang, W. & 7 other authors ( 2002;). Risk factors for Helicobacter pylori resistance in the United States: the Surveillance of H.pylori Antimicrobial Resistance Partnership (SHARP) study, 1993–1999. Ann Intern Med 136, 13–24.[CrossRef]
    [Google Scholar]
  18. McNulty, C., Owen, R., Tompkins, D., Hawtin, P., McColl, K., Price, A., Smith, G., Teare, L. & PHLS Helicobacter Working Group ( 2002;). Helicobacter pylori susceptibility testing by disc diffusion. J Antimicrob Chemother 49, 601–609.[CrossRef]
    [Google Scholar]
  19. Mégraud, F. ( 2001;). Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resistance Updates 4, 178–186.[CrossRef]
    [Google Scholar]
  20. NCCLS ( 1999;). Performance Standards for Antimicrobial Susceptibility Testing. Approved Standard M7-A5: Informational Supplement M100-S10. Wayne, PA: National Committee for Clinical Laboratory Standards.
  21. NICE ( 2003;). Dyspepsia: Managing Adult Patients in Primary Care, 2nd draft. London: National Guideline Research and Development Unit. www.nice.org.uk (accessed 23 August 2004).
  22. Owen, R. J. ( 2002;). Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 50, 285–289.[CrossRef]
    [Google Scholar]
  23. Owen, R. J., Xerry, J., Peters, T. M. & Teare, E. L. ( 2002;). Surveillance and clinical relevance of vacA genotypes of Helicobacter pylori infecting dyspeptic patients in mid-Essex. Commun Dis Public Health 5, 106–111.
    [Google Scholar]
  24. Parsons, H. K., Carter, M. J., Sanders, D. S., Winstanley, T. & Lobo, A. J. ( 2001;). Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 15, 1473–1478.[CrossRef]
    [Google Scholar]
  25. SIGN ( 2002;). Dyspepsia: A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network. http://www.sign.ac.uk/pdf/sign68.pdf (accessed 8 June 2004).
  26. Suerbaum, S. & Michetti, P. ( 2002;). Helicobacter pylori infection. N Eng J Med 347, 1175–1186.[CrossRef]
    [Google Scholar]
  27. Teare, L., Peters, T., Saverymuttu, S., Owen, R. & Tiwari, I. ( 1999;). Antibiotic resistance in Helicobacter pylori. Lancet 353, 241–242.[CrossRef]
    [Google Scholar]
  28. Thyagarajan, S. P., Ray, P., Das, B. K. & 10 other authors ( 2003;). Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol 18, 1373–1378.[CrossRef]
    [Google Scholar]
  29. Vyse, A. J., Gay, N. J., Hesketh, L. M., Andrews, N. J., Marshall, B., Thomas, H. I., Morgan-Capner, P. & Miller, E. ( 2002;). The burden of Helicobacter pylori infection in England and Wales. Epidemiol Infect 128, 411–417.
    [Google Scholar]
  30. Wolle, K., Leodolter, A., Malfertheiner, P. & Konig, W. ( 2002;). Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 51, 705–709.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45896-0
Loading
/content/journal/jmm/10.1099/jmm.0.45896-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error